ReviewAnnals of the rheumatic diseases2006
Natalizumab and progressive multifocal leucoencephalopathy.
Review in Annals of the rheumatic diseases, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 56 citations in OpenAlex.
- Trial
- Long-Term Safety of Ontamalimab in Patients with Moderate to Severe Inflammatory Bowel Disease.Clinical and experimental gastroenterology · 2026Article
- The Role and Application of MAdCAM-1/α4β7-Induced Lymphocyte Migration in Inflammatory Enterohepatic Diseases.Biomedicines · 2025Review
- VCAM-1 as a common biomarker in inflammatory bowel disease and colorectal cancer: unveiling the dual anti-inflammatory and anti-cancer capacities of anti-VCAM-1 therapies.Cancer metastasis reviews · 2025Review
- Choosing Therapies in Ulcerative Colitis.Journal of the Canadian Association of Gastroenterology · 2024Article
- Article
- Review
- Review
- Infections in the Era of Targeted Therapies: Mapping the Road Ahead.Frontiers in medicine · 2020Article
- Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease.Clinical pharmacokinetics · 2018Review
- Natalizumab therapy is associated with changes in serum JC virus antibody indices over time.Journal of neurology · 2017Article
- Cytokine Signaling in Multiple Sclerosis and Its Therapeutic Applications.Medical sciences (Basel, Switzerland) · 2017Review
- Functional knock down of VCAM1 in mice mediated by endoplasmatic reticulum retained intrabodies.mAbs · 2014Article
- Rapidly progressive cerebellar ataxia in West Wales.BMJ case reports · 2013Article
- Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients.Journal of neurology, neurosurgery, and psychiatry · 2013Article
- Pre-existing T- and B-cell defects in one progressive multifocal leukoencephalopathy patient.PloS one · 2012Article
- Analysis of behavior and trafficking of dendritic cells within the brain during toxoplasmic encephalitis.PLoS pathogens · 2011Article
- [Progressive multifocal leukoencephalopathy. Undesirable side effect of immunotherapy].Der Nervenarzt · 2009Review
- Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current data suggest that as many as 1 in 1000 treated individuals may develop progressive multifocal leucoencephalopathy (PML) in concert with the use of natalizumab. Natalizumab was withdrawn in early 2005. The present paper provides a comprehensive description of PML and reviews the role of natalizumab in the pathogenesis of PML. It is likely that use of drugs which cause specific perturbations of the immune system will be accompanied by similar rare infections. Thus researchers should be on the alert when using such agents in clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.